The listed products fall under the category of anti-fibrotic medicines, which are primarily used in the treatment of lung conditions such as Idiopathic Pulmonary Fibrosis (IPF) and other chronic fibrotic diseases. Medicines like Pirfenex (Pirfenidone) and Nintedanib-based brands such as Nintib, Nintena, Nindanib, and Nintabid work by slowing down the progression of fibrosis (scarring) in lung tissues. They help reduce inflammation, inhibit fibroblast activity, and prevent excessive tissue thickening, thereby improving lung function and delaying disease progression. These medications are an essential part of long-term respiratory care and are prescribed under strict medical supervision, as they require regular monitoring for effectiveness and potential side effects.